Article

Pain and dysfunction related to tendinopathy are often refractory to traditional
treatments and offer a unique challenge to physicians, because no gold standard
treatment exists. Injectable biologics may represent a new modality in
conjunction with a multifaceted treatment approach. Platelet-rich plasma (PRP)
injections are not associated with the systemic or tendon degradation risks of
corticosteroids or the inherent risks of surgery. Studies are promising but have
not been replicated with high-powered evidence at the clinical level. Further
evidence to expand understanding of the role of PRP in the treatment of
tendinopathy is needed.
CI - Copyright (c) 2014 Elsevier Inc. All rights reserved.

Langue : ANGLAIS